We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
12 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryZilbrysq (zilucoplan) has been approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Lacosamide
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment for Certolizumab pegol
-
Prescription medicine registrationActive ingredients: certolizumab pegol.
-
Prescription medicine registrationActive ingredients: brivaracetam.
-
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Brivaracetam
-
Australian Public Assessment Report (AusPAR)
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Certolizumab